• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CTI BioPharma Corp. (DE)

    4/14/23 8:25:50 AM ET
    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTIC alert in real time by email
    SC 13G 1 ctibiocorp13g.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    CTI BioPharma Corp.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001per share

    (Title of Class of Securities)

     

     

    12648L601

    (CUSIP Number)

     

     

    April 4, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 12648L601

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization California

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 7,018,046

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 7,018,046
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 7,018,046

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 12648L601

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 7,018,046

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 7,018,046
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 7,018,046

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. 12648L601

    Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 7,018,046

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 7,018,046
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 7,018,046

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 12648L601

     

    Item 1.

     

    (a)Name of Issuer

    CTI BioPharma Corp.

     

    (b)Address of Issuer’s Principal Executive Offices

    3101 Western Avenue, Suite 800, Seattle, WA 98121

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:


    Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Jon M. Plexico (collectively, the “Filers”)

     

    The General Partner is the general partner and investment adviser of investment funds, including the Partnership. Mr. Plexico is a control person of the General Partner. The other control person of the General Partner has previously filed a Schedule 13G with respect to his beneficial ownership of the Stock. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.001per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 12648L601
     5 
    CUSIP No. 12648L601
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 131,835,892 shares of Common Stock outstanding as of February 21, 2023, as reported in the Issuer’s Form 10-K filed on March 6, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of the General Partner and Mr. Plexico

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     6 
    CUSIP No. 12648L601

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 13, 2023

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By:
    /s/ Timothy P. Lynch

    Timothy P. Lynch, Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By:
    Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch

    Timothy P. Lynch, Managing Member

     

     

     

    /s/ Jon M. Plexio

    Jon M. Plexico

     

       
     7 
    CUSIP No. 12648L601

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By:
    /s/ Timothy P. Lynch
    Managing Member

     

      STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member
     
    /s/ Jon M. Plexico
      /s/ Timothy P. Lynch

     

    Get the next $CTIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTIC

    DatePrice TargetRatingAnalyst
    10/17/2022$13.00Outperform
    SVB Leerink
    9/1/2022$13.00Buy
    Jefferies
    7/7/2022$10.00Outperform
    Cowen
    3/2/2022$4.00 → $5.00Market Outperform
    JMP Securities
    3/2/2022$5.00 → $8.00Buy
    Needham
    12/1/2021$6.00 → $5.00Buy
    Needham
    8/9/2021$7.00Buy
    BTIG Research
    More analyst ratings

    $CTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Bvf Partners L P/Il

      4 - CTI BIOPHARMA CORP (0000891293) (Issuer)

      6/28/23 6:26:13 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Parks Diane L.

      4 - CTI BIOPHARMA CORP (0000891293) (Issuer)

      6/26/23 4:05:38 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Fischer Laurent

      4 - CTI BIOPHARMA CORP (0000891293) (Issuer)

      6/26/23 4:05:31 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

      SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech. "Diane is an accomplished leader with considerable experience driving the successful planning, launch, and commercialization of new medicines in hematology and oncology," said Laurent Fischer, M.D., Chairman of the Board of CTI Biopharma. "We are pleased to have Diane join CTI's Board of Directors at this pivotal time as we advance our JAK2/IRAK-1 inhibitor pacritinib towards a po

      8/24/21 7:00:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    SEC Filings

    See more
    • SEC Form 15-12G filed by CTI BioPharma Corp. (DE)

      15-12G - CTI BIOPHARMA CORP (0000891293) (Filer)

      7/6/23 4:15:26 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CTI BioPharma Corp. (DE)

      EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)

      6/30/23 12:15:13 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CTI BioPharma Corp. (DE)

      EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)

      6/30/23 12:15:28 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink initiated coverage on CTI BioPharma with a new price target

      SVB Leerink initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $13.00

      10/17/22 7:38:54 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on CTI BioPharma with a new price target

      Jefferies initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $13.00

      9/1/22 7:25:53 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on CTI BioPharma with a new price target

      Cowen initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $10.00

      7/7/22 7:34:10 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. STOCKHOLM, June 24, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announced today that it has, through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra), successfully completed its tender offer to purchase all outstanding shares of common stock of CTI BioPharma Corp. (NASDAQ:CTIC) (CTI), at a price of USD 9.10 per sh

      6/24/23 6:49:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

      SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the "Annual Meeting") which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting. The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) ("Sobi") to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of M

      5/30/23 4:35:00 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sobi to Acquire CTI BioPharma

      Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi

      5/10/23 1:06:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Financials

    Live finance-specific insights

    See more
    • Sobi to Acquire CTI BioPharma

      Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi

      5/10/23 1:06:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

      SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. To participate via telephone, please register in a

      5/1/23 4:46:00 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

      – Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022 oral presentation featured new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients – – Management to host webcast and conference call at updated time today at 8:30 a.m. ET – SEATTLE, March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo

      3/6/23 6:25:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by CTI BioPharma Corp. (DE) (Amendment)

      SC 13D/A - CTI BIOPHARMA CORP (0000891293) (Subject)

      6/28/23 1:51:34 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CTI BioPharma Corp. (DE)

      SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)

      4/14/23 8:25:50 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CTI BioPharma Corp. (DE)

      SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)

      3/24/23 4:49:08 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care